Fludarabine (Flu) and IV busulfan (Bu)±ATG:: Low toxicity conditioning regimen for stem cell transplantation (SCT) in AML and MDS -: Preliminary results.

被引：0
|
作者：
deLima, M
Shahjahan, M
Madden, T
Tran, HT
Gajewski, JL
Couriel, DR
Giralt, S
Donato, ML
Anderlini, P
Korbling, M
Khouri, I
Russell, JA
Champlin, RE
Andersson, BS
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Tom Baker Canc Clin, Dept Med, Calgary, AB, Canada
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5147
引用
收藏
页码：345B / 345B
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation
    Ohwada, Chikako
    Yamazaki, Shingo
    Shono, Katsuhiro
    Kayamori, Kensuke
    Hino, Yutaro
    Oshima-Hasegawa, Nagisa
    Muto, Tomoya
    Tsukamoto, Shokichi
    Mitsukawa, Shio
    Takeda, Yusuke
    Mimura, Naoya
    Takeuchi, Masahiro
    Iseki, Tohru
    Onoda, Masahiro
    Yokota, Akira
    Suzuki, Takaaki
    Ishii, Itsuko
    Nakaseko, Chiaki
    Sakaida, Emiko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (06) : 664 - 673
  • [22] A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS
    Andersson, Borje S.
    Thall, Peter
    Valdez, Benigno C.
    Ma, Junsheng
    Chen, Julianne
    Ahmed, Sairah
    Alousi, Amin M.
    Bashir, Qaiser
    Ciurea, Stefan O.
    Gulbis, Alison
    Hosing, Chitra
    Jones, Roy B.
    Kawedia, Jitesh
    Kebriaei, Partow
    Kornblau, Steven M.
    Myers, Alan
    Oran, Betul
    Rezvani, Katayoun
    Shah, Nina
    Shpall, Elizabeth J.
    Parmar, Simrit
    Popat, Uday R.
    Nieto, Yago
    Champlin, Richard E.
    BLOOD, 2020, 136
  • [23] Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS
    J De La Serna
    J Sanz
    A Bermúdez
    M Cabrero
    D Serrano
    C Vallejo
    V Gómez
    J M Moraleda
    S G Perez
    M D Caballero
    E Conde
    J J Lahuerta
    G Sanz
    Bone Marrow Transplantation, 2016, 51 : 961 - 966
  • [24] IV Busulfan (Bu) with fludarabine (Flu) or cyclophosphamide (Cy) - Comparing ablative conditioning regimens for allogeneic transplantation in AMLIMDS.
    de Lima, M
    Couriel, D
    Shahjahan, M
    Alamo, J
    Thall, PF
    Russell, J
    Anderlini, P
    Giralt, S
    Shpall, EJ
    Jones, RB
    Champlin, RE
    Andersson, BS
    BLOOD, 2004, 104 (11) : 31A - 31A
  • [25] Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS
    De La Serna, J.
    Sanz, J.
    Bermudez, A.
    Cabrero, M.
    Serrano, D.
    Vallejo, C.
    Gomez, V.
    Moraleda, J. M.
    Perez, S. G.
    Caballero, M. D.
    Conde, E.
    Lahuerta, J. J.
    Sanz, G.
    BONE MARROW TRANSPLANTATION, 2016, 51 (07) : 961 - 966
  • [26] Nonmyeloablative stem cell transplantation using fludarabine-based conditioning regimen (preliminary results).
    Kim, I
    Jung, JY
    Lee, DH
    Song, HH
    Lee, MH
    Yoon, SS
    Kim, CS
    Park, S
    Kim, BK
    Kim, NK
    BLOOD, 2001, 98 (11) : 376B - 376B
  • [27] Fludarabine and treosulfan conditioning for allogeneic stem cell transplantation (SCT) in patients with AML and MDS not eligible for standard myeloablative conditioning: the role of treosulfan dose
    Shimoni, A.
    Peccatori, J.
    Shem-Tov, N.
    Lo Russo, A.
    Yerushalmi, R.
    Bernardi, M.
    Nagler, A.
    Ciceri, F.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S220 - S220
  • [28] MYELOABLATIVE CONDITIONING WITH FLUDARABINE AND (IV) BUSULFAN (F-BU4) FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
    Talbi, A.
    Nacer, R. Ahmed
    Benakli, M.
    Mehdid, F.
    Belhadj, R.
    Rahmoune, N.
    Baazizi, M.
    Ouali, D. Ait
    Bouarab, H.
    Harieche, F.
    Hamladji, R. M.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S186 - S187
  • [29] Comparable outcomes for Fludarabine/TBI versus Fludarabine/Treosulfan conditioning prior to allogeneic stem cell transplantation (Allo-SCT) in AML and MDS patients
    Berning, P.
    Kolloch, L.
    Reicherts, C.
    Call, S.
    Marx, J.
    Floeth, M. P.
    Esseling, E.
    Schliemann, C.
    Lenz, G.
    Stelljes, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 140 - 140
  • [30] Fludarabine, IV busulfan and antithymocyte globulins-based reduced-toxicity conditioning regimen (FB3) prior to allogeneic stem cell transplantation (allo-SCT): results of a multicentre prospective trial
    Mohty, M.
    Blaise, D.
    Labopin, M.
    Milpied, N.
    Furst, S.
    Tabrizi, R.
    Guillaume, T.
    Vigouroux, S.
    El-Cheik, J.
    Delaunay, J.
    Le Gouill, S.
    Moreau, P.
    Chevallier, P.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S61 - S61
12345